Lexeo Therapeutics (LXEO) Cash from Financing Activities (2022 - 2026)

Lexeo Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 22190.91% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $219.2 million (up 164739.1% YoY), while the FY2025 annual figure was $216.8 million, up 144.2% from the prior year.
• Cash from Financing Activities came in at $2.5 million for Q1 2026 at Lexeo Therapeutics, down from $143.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $143.8 million in Q4 2025 to a low of -$98000.0 in Q1 2023.
• A 5-year average of $29.4 million and a median of $171500.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 101.84% in 2024 and soared 148318.56% in 2025, its largest moves.
• Lexeo Therapeutics' Cash from Financing Activities stood at -$81000.0 in 2022, then soared by 123644.44% to $100.1 million in 2023, then slumped by 100.1% to -$97000.0 in 2024, then jumped by 148318.56% to $143.8 million in 2025, then plunged by 98.29% to $2.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.5 million, $143.8 million, and $52000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison